AU2009305612B2 - Modified blood factors comprising a low degree of water soluble polymer - Google Patents

Modified blood factors comprising a low degree of water soluble polymer Download PDF

Info

Publication number
AU2009305612B2
AU2009305612B2 AU2009305612A AU2009305612A AU2009305612B2 AU 2009305612 B2 AU2009305612 B2 AU 2009305612B2 AU 2009305612 A AU2009305612 A AU 2009305612A AU 2009305612 A AU2009305612 A AU 2009305612A AU 2009305612 B2 AU2009305612 B2 AU 2009305612B2
Authority
AU
Australia
Prior art keywords
factor viii
factor
psa
molecule
fviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009305612A
Other languages
English (en)
Other versions
AU2009305612A1 (en
Inventor
Hanspeter Rottensteiner
Juergen Siekmann
Peter Turecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2009305612A1 publication Critical patent/AU2009305612A1/en
Application granted granted Critical
Publication of AU2009305612B2 publication Critical patent/AU2009305612B2/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2009305612A 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer Active AU2009305612B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10642408P 2008-10-17 2008-10-17
US61/106,424 2008-10-17
PCT/US2009/061023 WO2010045568A1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer

Publications (2)

Publication Number Publication Date
AU2009305612A1 AU2009305612A1 (en) 2010-04-22
AU2009305612B2 true AU2009305612B2 (en) 2015-05-21

Family

ID=41650072

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009305612A Active AU2009305612B2 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer

Country Status (20)

Country Link
US (4) US20100099616A1 (https=)
EP (3) EP2349342B1 (https=)
JP (2) JP5785872B2 (https=)
KR (2) KR101929641B1 (https=)
AU (1) AU2009305612B2 (https=)
BR (1) BRPI0920259A8 (https=)
CA (1) CA2738679A1 (https=)
CY (1) CY1120921T1 (https=)
DK (1) DK2349342T3 (https=)
ES (1) ES2692172T3 (https=)
HR (1) HRP20181454T1 (https=)
HU (1) HUE039906T2 (https=)
LT (1) LT2349342T (https=)
MX (1) MX2011004085A (https=)
NZ (1) NZ592688A (https=)
PL (1) PL2349342T3 (https=)
PT (1) PT2349342T (https=)
SI (1) SI2349342T1 (https=)
SM (1) SMT201800486T1 (https=)
WO (1) WO2010045568A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106110311A (zh) * 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US10238718B2 (en) 2014-08-04 2019-03-26 Csl Limited Factor VIII formulation
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
WO1994029370A1 (en) * 1993-06-08 1994-12-22 Enzon, Inc. Factor ix - polymeric conjugates
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO2004000366A1 (en) * 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
US20040235734A1 (en) * 2003-02-26 2004-11-25 Bossard Mary J. Polymer-factor VIII moiety conjugates
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US20060115876A1 (en) * 2004-11-12 2006-06-01 Bayer Healthcare Llc Site-directed modification of FVIII
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US20070244301A1 (en) * 2006-03-31 2007-10-18 Juergen Siekmann Pegylated factor VIII
US20070254840A1 (en) * 2000-06-30 2007-11-01 Nelsestuen Gary L High Molecular Weight Derivatives of Vitamin K-Dependent Polypeptides
WO2008074032A1 (en) * 2006-12-15 2008-06-19 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
WO2008082669A2 (en) * 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
JP2006517400A (ja) 2002-12-19 2006-07-27 ネクター セラピューティクス アラバマ，コーポレイション シアノビリン変異体−ポリマー接合体
KR20060003862A (ko) * 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
CA2591852A1 (en) * 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
WO1994029370A1 (en) * 1993-06-08 1994-12-22 Enzon, Inc. Factor ix - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US20070254840A1 (en) * 2000-06-30 2007-11-01 Nelsestuen Gary L High Molecular Weight Derivatives of Vitamin K-Dependent Polypeptides
WO2004000366A1 (en) * 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
US7199223B2 (en) * 2003-02-26 2007-04-03 Nektar Therapeutics Al, Corporation Polymer-factor VIII moiety conjugates
US20040235734A1 (en) * 2003-02-26 2004-11-25 Bossard Mary J. Polymer-factor VIII moiety conjugates
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US20060115876A1 (en) * 2004-11-12 2006-06-01 Bayer Healthcare Llc Site-directed modification of FVIII
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US20070244301A1 (en) * 2006-03-31 2007-10-18 Juergen Siekmann Pegylated factor VIII
WO2008074032A1 (en) * 2006-12-15 2008-06-19 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
WO2008082669A2 (en) * 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSTIN, J ET AL (2000) Bioconjugate Chem 11: 387-396 *

Also Published As

Publication number Publication date
KR20110071012A (ko) 2011-06-27
EP2349342B1 (en) 2018-06-27
JP5785872B2 (ja) 2015-09-30
PL2349342T3 (pl) 2019-01-31
KR20160103173A (ko) 2016-08-31
DK2349342T3 (en) 2018-10-08
EP3437661A1 (en) 2019-02-06
CA2738679A1 (en) 2010-04-22
NZ592688A (en) 2012-12-21
US20160199503A1 (en) 2016-07-14
PT2349342T (pt) 2018-10-26
JP2012505917A (ja) 2012-03-08
BRPI0920259A2 (pt) 2016-01-05
US20190160178A1 (en) 2019-05-30
EP3620177A1 (en) 2020-03-11
WO2010045568A1 (en) 2010-04-22
BRPI0920259A8 (pt) 2017-09-19
KR101929641B1 (ko) 2018-12-14
ES2692172T3 (es) 2018-11-30
HRP20181454T1 (hr) 2018-12-14
AU2009305612A1 (en) 2010-04-22
MX2011004085A (es) 2011-09-27
US20100099616A1 (en) 2010-04-22
JP2015110676A (ja) 2015-06-18
US20120076749A1 (en) 2012-03-29
SMT201800486T1 (it) 2018-11-09
SI2349342T1 (sl) 2018-10-30
HUE039906T2 (hu) 2019-02-28
CY1120921T1 (el) 2019-12-11
LT2349342T (lt) 2018-10-10
EP2349342A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
AU2009305612B2 (en) Modified blood factors comprising a low degree of water soluble polymer
JP5715983B2 (ja) ポリマー−フォンビルブラント因子結合体
US20090247459A1 (en) Modified recombinant factor viii and von willebrand factor and methods of use
EP2245456B1 (en) Method and compositions for specifically detecting physiologically acceptable polymer molecules
HK1105276B (en) Polymer-von willebrand factor-conjugates
HK1127300A (en) Pegylated factor viii

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BAXALTA GMBH; BAXALTA INCORPORATED

Free format text: FORMER OWNER WAS: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.

PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA INCORPORATED; BAXALTA GMBH